Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02812524
PHASE1

Ipilimumab for Head and Neck Cancer Patients

Sponsor: Providence Health & Services

View on ClinicalTrials.gov

Summary

This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.

Official title: Intratumoral Ipilimumab in Head and Neck Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2016-11-18

Completion Date

2025-12

Last Updated

2025-03-10

Healthy Volunteers

No

Interventions

DRUG

Intratumoral Ipilimumab

Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.

Locations (1)

Portland Providence Medical Center

Portland, Oregon, United States